Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: Should You Buy?

Inspire Medical Systems (INSP) is set to report Q2 2025 earnings on August 4, with consensus estimates forecasting $0.22 EPS, a 31.3% year-over-year decline, on revenues of $215.05 million, up 9.8%. Despite the expected EPS dip, INSP's positive Zacks Earnings ESP of +9.09% combined with a Zacks Rank #3 suggests a high probability of beating consensus EPS estimates, consistent with its record of exceeding expectations in the past four quarters. This positions INSP as a compelling earnings-beat candidate, though overall stock performance will also depend on management commentary and broader market conditions.

Analysis

Inspire Medical Systems (INSP) presents a mixed but compelling pre-earnings profile ahead of its August 4th report. Consensus estimates project a dichotomous quarter, with revenues expected to grow 9.8% year-over-year to $215.05 million, while earnings per share are forecasted to decline by 31.3% to $0.22. Despite this anticipated bottom-line contraction, quantitative signals strongly suggest a potential for a positive earnings surprise. The company's Zacks Earnings ESP (Expected Surprise Prediction) is a significant +9.09%, indicating that the most recent analyst estimates are more bullish than the standing consensus. This, combined with a Zacks Rank of #3 (Hold) and a consistent history of beating EPS estimates over the last four quarters—including a +143.48% surprise in the prior quarter—creates a high-probability scenario for an earnings beat. While the consensus EPS estimate has remained unchanged for 30 days, the positive ESP implies recent information has shifted near-term expectations upward. The ultimate stock performance will likely depend on whether an earnings beat is substantial enough to overshadow the headline earnings decline and, more critically, on the forward-looking guidance provided by management during the earnings call.

Key Decisions for Investors

• Given the strong statistical likelihood of an earnings beat based on the +9.09% Earnings ESP and a history of positive surprises, investors could consider this a compelling short-term catalyst-driven opportunity.
• Investors should look beyond the headline EPS number and scrutinize the revenue figures and management's guidance, as the projected 9.8% top-line growth is critical to the long-term thesis, especially against a backdrop of declining profitability.
• Be prepared for potential volatility, as a mere earnings beat may not be sufficient to drive the stock higher if management's commentary on business conditions and the reasons for the 31.3% YoY earnings decline disappoints investors.